CD19 – Page 2 – Communicable Diseases Research

Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia

항-CD19 키메라 항원 수용체 T 세포 유도 B 세포 무형성증이 있는 젊은 환자에서 SARS-CoV-2 백신 접종에 대한 면역 반응

Article

Published on 2022-07-012022-09-11
Journal: Transplantation and cellular therapy [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술,

Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients

리툭시맙 치료 환자에서 COVID-19 백신 접종에 대한 체액 반응 장애의 위험 요인

Observational Study

Published on 2022-06-282022-09-11
Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상, 진단, 치료기술,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis antibody antibody levels Antibody Response B cell B cells CD19 Characteristics chronic inflammatory rheumatic disorder consecutive patient consecutive patients coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 vaccination cut-off value demographics detectable disease Factor humoral Humoral response identify IgG antibody independent Inflammatory monitoring monotherapy MTX multivariate multivariate analyses negative Odds ratio Patient patients produced receiving recruited respiratory rheumatic disease Rheumatic diseases rituximab RTX SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 vaccination seroconversion rate seroconversion rates serology Seropositivity severe acute respiratory syndrome Coronavirus Spike protein Spike proteins therapy two-dose regimen undetectable usual care vaccination were measured
[DOI] 10.1093/rheumatology/keab815 PMC 바로가기 [Article Type] Observational Study

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity

코로나바이러스 질병 2019 심각도의 예후 마커로서의 프로그램된 세포 사멸-1/프로그램된 세포 사멸-1 리간드

Article

Published on 2022-06-202022-09-11
Journal: Cells [Category] MERS, 바이오마커,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 analysed association B cells B lymphocyte baseline Biomarker CD19 Cell Control controls coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 severity current disease disease mortality disease severity dysregulation evaluated expression groups hospitalized patient hospitalized patients immune immune dysregulation immunophenotype In-hospital increase Increased Infection intensive care Laboratory Ligand lymphocyte Lymphocytes marker mechanical ventilation moderate moderate to severe Mortality notable oxygen oxygen support parameter patients with COVID-19 patients with moderate patients without COVID-19 PD-1 PD-L1 profile programmed cell death programmed cell death protein programmed cell death protein 1 Protein Research respiratory severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe COVID-19 severity survival T cell T cells Treatment were used
[DOI] 10.3390/cells11121978 PMC 바로가기 [Article Type] Article

Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency

공통 가변성 면역 결핍증에서 2개의 ChAdOx1 nCoV-19 후 BNT162b2 부스팅에 의해 유도된 특정 항체 및 T-세포 반응

Article

Published on 2022-06-172022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 immunoglobulin Anti-spike antibody autologous BNT162b2 BNT162b2 vaccine booster vaccination CD19 CD19+ CD3+ CD3+CD4+ CD3+CD8+ CD4+ CD45 CD45+ CD8+ Cell cell count cell counts cell-mediated response ChAdOx1 ChAdOx1 nCoV-19 changes in common common variable immunodeficiency common variable immunodeficiency (CVID) Control Coronavirus-2 COVID-19 infection cumulative cut-off value CVID decrease ELISPOT ELISpot assay evaluated except for flow cytometric healthy control healthy controls healthy individual healthy individuals humoral IFN-γ IFN-γ ELISPOT IFN-γ ELISpot assay IFN-γ producing T cells immune response immunodeficiency Immunoglobulin Immunoglobulin G immunosuppressive immunosuppressive therapy individual interferon interferon-γ Killer cell less Lymphocytes measure morbidity natural killer natural killer cell not different not significant Patient patients positive Primary Immunodeficiency producing protein S raised receiving response Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 shown Side effects significant difference significant differences significantly significantly lower Specific statistically stem cell Stem cell transplantation T cell T cell response T cells tested therapy These data vaccination Vaccinations variable virus-specific T cell virus-specific T-cell with COVID-19
[DOI] 10.3389/fimmu.2022.907125 PMC 바로가기 [Article Type] Article

Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis

다발성 경화증 환자의 항-COVID19 백신 접종에 대한 항체 매개 반응에 대한 질병 조절 치료의 효과

Article

Published on 2022-06-012022-09-11
Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Adverse adverse event adverse events age aligned analysed anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment Anti-spike antibody Antibody Response CD19 CD19+ CD20 CD20 deplething therapies cell count cell-mediated immune cell-mediated immune response Cohort correlated COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccines depleting detectable diagnosed Disease-modifying therapies Effect elicited event female fingolimod Follow-up Frequency IgG antibody immune response investigation material median median age Multiple multiple sclerosis non-responders Patient proportion protective immune response Protein receiving recorded Responder responders symptomatic therapy titre treated Treatment vaccination Vaccine was reduced
[DOI] 10.1007/s00415-022-11003-3 PMC 바로가기 [Article Type] Article

Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic

COVID-19 대유행 기간 동안 다발성 경화증 환자에서 ocrelizumab의 맞춤형 B 세포 맞춤형 투여

Observational Study

Published on 2022-06-012022-09-12
Journal: Multiple sclerosis (Houndmills, Basingstoke, Engla [Category] MERS, 임상, 진단,

[키워드] B-cell CD19 COVID-19 COVID-19 pandemic disability Disease activity dose EDSS Efficacy Follow-up incidence interval intervals magnetic resonance imaging MRI Multiple multiple sclerosis Neurofilament light Ocrelizumab Patient personalized dosing. progression radiological remained repeated reported Research scale serum significantly status
[DOI] 10.1177/13524585211028833 PMC 바로가기 [Article Type] Observational Study

SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease

SARS-CoV-2-mRNA 부스터 백신 접종은 면역 저하 환자의 무반응 및 조기 항체 약화를 역전시킵니다 - 고형암, 다발성 골수종 및 염증성 장 질환 환자의 면역 반응을 비교하는 4상 연구

Clinical Trial

Published on 2022-05-122022-09-12
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] analyzed anamnestic response anamnestic vaccine-specific response antibody Antibody testing Autoimmune disease B-cell BNT162b2 booster booster vaccination Cancer patients CD19 cellular cellular response Control control group controls correlated COVID-19 cytokine response declined Effectiveness EudraCT group help highest humoral humoral and cellular vaccine-specific responses IBD identify IFN-γ response IgG IgG level IL-2 immune responses immunodeficiency IMPROVE individual Inflammatory bowel disease inhibitor inhibitors intervals knowledge mRNA mRNA vaccination mRNA-1273 Multiple Multiple myeloma Myeloma neutralizing antibody non-infected Open-label Patient patients patients treated patients under immunosuppression/immunomodulation Patients with cancer persistence phase response SARS-CoV-2 SARS-CoV-2 mRNA vaccination SARS-CoV-2 vaccination second dose Solid solid tumor SOT TNF-α Trial undetectable vaccination Vaccine waning of immune responses.
[DOI] 10.3389/fimmu.2022.889138 PMC 바로가기 [Article Type] Clinical Trial

Antibody response to COVID-19 vaccination in patients with lymphoma

림프종 환자에서 코로나19 예방접종에 대한 항체 반응

Observational Study

Published on 2022-05-012022-09-12
Journal: International journal of hematology [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type

다발성경화증 환자에서 SARS-COV-2 백신에 대한 체액성 반응: DMT, 림프구 수, 면역글로불린 및 백신 유형의 영향을 탐구하는 사례 시리즈

Article

Published on 2022-05-012022-09-11
Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Affect age antibody association B-cell case sery CD19 Cell Certain disease correlation COVID19 depleting detectable disease disease phenotype disorder DMT dose Exploratory analysis females fumarate Gender group humoral Humoral response Hypogammaglobulinemia immune response immunoglobulins immunological immunological characteristics lymphocyte Lymphocyte count lymphocyte counts lymphopenia Mild Multiple multiple sclerosis no differences Patient performed positive positive patient positive patients Quantitative response to vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV2 seroconversion rate seroconversion rates Spike protein subgroup subgroups tested the spike protein therapy vaccination Vaccine vaccine response Vaccines variable verification
[DOI] 10.1016/j.msard.2022.103785 PMC 바로가기 [Article Type] Article

The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-γ release by natural killer cells

비활성화된 SARS-CoV-2 백신(CoronaVac) 및/또는 SARS-CoV-2 감염이 항체 수준, 형질모세포, 수명이 긴 형질 세포 및 자연 살해 세포에 의한 IFN-γ 방출에 미치는 영향

Article

Published on 2022-04-202022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] anti-S anti-SARS-CoV-2 spike protein anti-spike antibody antibody Antibody Response B cell CD138 CD19 CD27 Cell CoronaVac COVID-19 detectable dose Elecsy elicited ELISA kit evaluated flow cytometry four groups Germinal center group groups HCW HCWs healthcare worker Healthcare workers IAV IFN-gamma IFN-γ immunization inactivated Inactivated vaccine interferon gamma İstanbul Killer cell long-lived plasma cell long-lived plasma cells Lymph node lymph nodes median memory B cell memory B cells Migration natural infection natural killer natural killer cell no difference not differ patients percentage phenotype Plasma cells plasmablast plasmablasts qPCR RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine significantly higher significantly lower Spike protein study groups Test the antibody response the study group Turkey uninfected Vaccine Version virion was performed were measured Whole virion inactivated vaccine.
[DOI] 10.1016/j.vaccine.2022.03.001 PMC 바로가기 [Article Type] Article